# A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult

> **NCT03784885** · PHASE2 · COMPLETED · sponsor: **Advagene Biopharma Co. Ltd.** · enrollment: 345 (actual)

## Conditions studied

- Influenza Infection

## Interventions

- **BIOLOGICAL:** AD07010
- **BIOLOGICAL:** Inactivated trivalent influenza vaccine

## Key facts

- **NCT ID:** NCT03784885
- **Lead sponsor:** Advagene Biopharma Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2018-01-07
- **Final completion:** 2018-10-30
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2018-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03784885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03784885, "A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03784885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*